Cd23 binding molecules and methods of use thereof
AssigneeBiogen Idec MA Inc.
InventorsScott Glaser, Brian Robert Miller, Alexey Alexandrovich Lugovskoy, Stephen Demarest, Ann Maclaren, William B. Snyder
Life of this patent
Estimating the term…
Abstract
The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL.
Claims72
A multivalent CD23 binding molecule comprising more than two CD23 binding moieties, wherein said binding molecule specifically crosslinks at least two distinct human CD23 molecules on the surface of an immune cell, thereby inducing apoptosis of the immune cell.
A tetravalent CD23 antibody molecule comprising four CD23 binding moieties and two heavy chain polypeptides, wherein two of said binding moieties are provided by an IgG antibody and two of said binding moieties are provided by two scFv molecules linked or fused to said IgG antibody.
A stabilized scFv molecule having binding specificity for CD23, wherein the stabilized scFv molecule has a T50 of greater than 55° C.
A method of inducing CD23-mediated caspase-3 or PARP cleavage in a cancer cell bearing CD23, comprising contacting the cancer cell with a multivalent CD23 binding molecule comprising at least four CD23 binding moieties, wherein said binding molecule binds to FcγR and specifically crosslinks at least two distinct human CD23 molecules on the surface of the cancer cell.
Dependencies are inferred from the claim text.